Volume Support/Assist Control Mode Ventilation and Diaphragmatic Atrophy
NCT03901924
Recruiting
The objective of the study is to determine how controlled mode ventilation and support mode ventilation impact ventilator-free days and diaphragmatic atrophy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: The University of Chicago Medical Center, Chicago, Illinois +1 locations
Conditions: Mechanical Ventilation Complication
Register for Updates
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
NCT04172532
Recruiting
This phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced). M3814 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +41 locations
Conditions: Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
Register for Updates
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
NCT04310020
Recruiting
This phase II trial studies the side effects of radiation therapy followed by atezolizumab in treating patients with stage II or III non-small cell lung cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more cancer cells and have fewer side effects. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to g... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +162 locations
Conditions: Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Lung Non-Small Cell Carcinoma
Register for Updates
A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
NCT04715646
Recruiting
The purpose of the study is to evaluate the long-term safety and tolerability of brivaracetam.
Gender:
ALL
Ages:
1 month and above
Trial Updated:
06/03/2025
Locations: Ep0156 259, Hawthorne, New York +33 locations
Conditions: Epilepsy
Register for Updates
ATEMPT 2.0: Adjuvant T-DM1 vs TH
NCT04893109
Recruiting
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM1, Kadcyla) * Trastuzumab SC (Herceptin Hylecta) * Paclitaxel
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California +49 locations
Conditions: Breast Cancer, HER2-positive Breast Cancer
Register for Updates
Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis
NCT05122559
Recruiting
This study evaluates the effectiveness of N-acetyl cysteine (NAC) in the treatment of progressive multiple sclerosis. Half of the patients will receive NAC, while the other half will receive a placebo.
Gender:
ALL
Ages:
Between 40 years and 70 years
Trial Updated:
06/03/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Register for Updates
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
NCT05241249
Recruiting
The primary objective of this study is to assess the impact of bethanechol therapy on R0 resection rates. The safety objective will be assessment of the safety and tolerability of bethanechol in combination with gemcitabine and nab-paclitaxel. The exploratory objective will be to evaluate genomic biomarkers associated with parasympathetic stimulation in pancreatic cancer, and the ability to reduce tumor growth rate.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Columbia University Medical Center, New York, New York
Conditions: Pancreas Cancer
Register for Updates
Impact of Suture Type on Pigment Disturbances in Patients of Skin of Color
NCT05408117
Recruiting
The present study assesses if dissolvable (fast gut) or non-dissolvable (polypropylene) epidermal sutures produce better cosmetic results in terms of dyspigmentation and scarring in patients of skin of color. Through a split-wound study design, patients undergoing standard elliptical excisions at least 3 cm in length will receive each suture type. Measurements of dyspigmentation and scarring will be made at 7 days (for the head and neck), 10 days (for the trunk and extremities), and 3 months for... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: UPMC Presbyterian, Pittsburgh, Pennsylvania +2 locations
Conditions: Scar
Register for Updates
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
NCT05533775
Recruiting
The purpose of this study is to evaluate the safety and efficacy of glofitamab, as monotherapy and in combination with a standard chemoimmunotherapy regimen: rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric and young adult participants with relapsed and refractory (R/R) mature B-cell non-Hodgkin lymphoma (B-NHL).
Gender:
ALL
Ages:
Between 6 months and 30 years
Trial Updated:
06/03/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +23 locations
Conditions: Mature B-Cell Non-Hodgkin Lymphoma
Register for Updates
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
NCT05595642
Recruiting
This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
06/03/2025
Locations: Pinnacle Research Group, Anniston, Alabama +453 locations
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Register for Updates
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
NCT05639114
Recruiting
The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
06/03/2025
Locations: Providence Medical Center, Burbank, California +173 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
Balance Tele-Rehab in Parkinson's Disease Parkinson's Disease
NCT05680597
Recruiting
This project will determine the feasibility and efficacy of remote assessment and treatment of balance disorders in people with Parkinson's disease.
Gender:
ALL
Ages:
Between 55 years and 85 years
Trial Updated:
06/03/2025
Locations: Oregon Health Science University, Portland, Oregon
Conditions: Parkinson Disease
Register for Updates